The ETV4 antibody is a key tool for studying the ETS translocation variant 4 (ETV4), a transcription factor belonging to the ETS family. ETV4. also known as PEA3 or E1A-F, regulates gene expression by binding to DNA via its conserved ETS domain, influencing processes like cell proliferation, differentiation, and apoptosis. It is implicated in cancer development, particularly in malignancies such as prostate, breast, and colorectal cancers, where its overexpression often correlates with tumor invasiveness, metastasis, and poor prognosis. ETV4 interacts with signaling pathways like MAPK/ERK and Wnt, modulating oncogenic targets (e.g., matrix metalloproteinases) to promote extracellular matrix remodeling and metastatic spread.
The ETV4 antibody is widely used in research to detect and quantify ETV4 protein levels in cells or tissues through techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP). It aids in exploring ETV4’s role in gene regulation, cellular transformation, and therapeutic resistance. Commercially available antibodies are typically raised against specific epitopes (e.g., N-terminal or C-terminal regions) and validated for specificity using knockdown/knockout controls. Researchers also utilize it to study ETV4’s interplay with other oncoproteins or tumor suppressors, providing insights into its mechanistic contributions to disease. However, antibody performance may vary depending on experimental conditions, emphasizing the need for proper validation in each application.